NetworkNewsBreaks – Vivos Therapeutics Inc. (NAS
Post# of 51
(Total Views: 136)
Posted On: 10/18/2021 3:56:30 PM
NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid Collaborate to Deliver Comprehensive Treatment Solution
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. “By teaming with Candid, we are aiming to provide patients with access not only to our highly effective Vivos System, but also simultaneous access to CandidPro’s novel orthodontic treatment. We believe the Vivos-Candid collaboration will provide for the first solution that seamlessly integrates sleep and orthodontic therapy to create better patient outcomes for treating OSA and enhance overall health and wellness across the board,” said Kirk Huntsman, Vivos chairman and CEO. “We are hopeful that this joint effort will increase market penetration and accelerate revenue growth for both companies as we each attract and expand our respective North American dental and healthcare networks.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. “By teaming with Candid, we are aiming to provide patients with access not only to our highly effective Vivos System, but also simultaneous access to CandidPro’s novel orthodontic treatment. We believe the Vivos-Candid collaboration will provide for the first solution that seamlessly integrates sleep and orthodontic therapy to create better patient outcomes for treating OSA and enhance overall health and wellness across the board,” said Kirk Huntsman, Vivos chairman and CEO. “We are hopeful that this joint effort will increase market penetration and accelerate revenue growth for both companies as we each attract and expand our respective North American dental and healthcare networks.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Vivos Therapeutics Inc. (VVOS) Stock Research Links
Scroll down for more posts ▼